Bli medlem
Bli medlem

Du är här

2021-07-08

Scandinavian ChemoTech starts a feasibility study in the USA

Today Scandinavian ChemoTech has signed an agreement with the US based company Diversified Consultant Group LLC that will be responsible for performing a feasibility study. This study is aiming to identify how Scandinavian ChemoTech should design a "Go-to-Market" strategy when launching its animal care product vetIQure in the USA.

The US market for vetIQure is of great significance as the Cancer therapy market for pets is estimated to over MUSD 800/y and growing with a double-digit rate.

Diversified Consultant Group LLC was founded by the CEO Danny Nesrallah, who has extensive experience from Business development of the older static generation of Electroporation in both the US and Middle East.

"To investigate our opportunities to enter the US market with our product vetIQure is both thrilling and exciting at the same time. We believe that we really have found the right partner to help us in the initial stages of our North American journey. Danny and his company also ensure that we have leverage from someone with a wide network of existing electroporation users." - says Mohan Frick, CEO of Scandinavian ChemoTech

For more information, please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se

Författare Cision

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.